Siti Mariam Abd Gani

Siti Mariam Abd Gani

Auto-generated profile, based on publicly available information

Siti Mariam Abd Gani

School of Tropical Medicine and Global Health, Nagasaki University , 1-12-4 Sakamoto, Nagasaki 852-8523

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in Journal of Global Health
Verified
Journal Article
Open access
SGSiti M Abd Gani
Siti M Abd Gani
MAMarcel Alied
Marcel Alied
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
As of 13 October 2022, Malaysia’s reported coronavirus disease 2019 (COVID-19) cases surpassed 4.8 million [1]. Up to that date, almost 65 million tests have been conducted, and the disease has claimed the lives of 36 410 people since its first detection in the country. Furthermore, the disease caused 7082 clusters, of which only 13 remained […]

30 May 2025 in Health Policy and Planning
Verified
Journal Article
Open access
SGSiti Mariam Abd Gani
Siti Mariam Abd Gani
NTNithiah Thangiah
Nithiah Thangiah
HAHirotsugu Aiga
Hirotsugu Aiga
Households with ill members often face financial hardship when seeking healthcare. Households mobilize their resources from various sources to pay for treatment costs. Financially, some households resort to borrowing money and selling their assets. This type of financial coping strategy is called distress financing (DF). This study aims to estimate the prevalence and determinants of DF among households with hospitalized members at University Malaya Medical Centre, Malaysia. It further explores the dynamics of DF and its impact on households’ welfare by employing a convergent mixed-method approach. Quantitative data were collected using a structured interview. Households having reported to either borrow money, sell their assets, and/or withdraw from an employee provident fund were categorized as those suffering DF. To explore how households coped with high medical expenses and the consequences of DF, seven households adopting more than one DF strategy were purposively selected for in-depth interview. Of 199 households, 22 (11.1%) reported undergoing DF. Psychological distress, medical indebtedness, and poverty were typical consequences of DF. During hardship, the social network played a principal role in alleviating the financial burden, further emphasizing the importance of kinship. Households undergoing catastrophic health expenditure, headed by Chinese ethnicity, living in states other than Selangor, and living in a rental house were 8.2, 4.6, 4.4, and 3.5 times more likely to undergo DF, respectively. Targeted assistance in removing financial barriers would assure the continuum of care among households possibly suffering DF, thereby improving their health outcomes.

1 June 2020 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SYS. A. Yeoh
S. A. Yeoh
KSK. Saxby
K. Saxby
ABA. Barron
A. Barron
SMS. Moore
S. Moore
SGS. Gani
S. Gani
MEM. Ehrenstein
M. Ehrenstein
Background: The patent for adalimumab originator expired in 2018 in the United Kingdom. Subsequently, four adalimumab biosimilars were launched. National Health Service England undertook a managed market share tender to ensure plurality of suppliers and price competition over the longer term. Each hospital was subsequently allocated a preferred brand of adalimumab biosimilar. Here we describe our experience of switching patients with inflammatory arthritis from adalimumab originator to the biosimilar, ABP 501 in a single centre. Objectives: To evaluate the proportion of patients successfully switched from adalimumab originator to ABP 501 focusing on drug retention, reasons for remaining on originator and reasons for switching back from biosimilar to originator. Methods: A retrospective analysis was completed on the cohort of 287 rheumatology patients who were prescribed adalimumab originator prior to the switch to ABP 501. Case notes were analysed to identify whether patients remained on biosimilar 24 weeks after switching from originator. Results: 99% patients on adalimumab originator (283/287) were switched to ABP 501 within 32 weeks, starting from February 2019. 1% (4/287) remained on originator due to a confirmed latex allergy, as the needle cover of the ABP 501 pre-filled syringe consists of dry natural rubber. 4% (12/283) of patients who switched to biosimilar reverted to originator (1 patient per 2 weeks over 24 weeks). 3% (9/283) of patients who switched to biosimilar were no longer receiving any adalimumab therapy. Reasons for ceasing therapy included recurrent infections (4/9) and progression to the next line of biologics/small molecule therapy (5/9). 93% (262/283) remained stable on ABP 501 (Table). Applications to revert to originator were reviewed by a Biosimilar Steering Group (BSG). The BSG assessment included a review of disease activity, reported symptoms and adverse reactions before and after the switch to biosimilar. Approval to revert to originator occurred in patients who had a clear increase in disease activity or newly reported adverse reactions. If the patient had active disease prior to switch, a change to non-adalimumab therapy would be recommended instead. Of the 12 patients who reverted to originator, 7 (58%) did so due to reduced effectiveness, 3 (25%) due to adverse reactions, and 2 (17%) due to both. Adverse reactions reported within 24 hours of the first injection included nausea, anxiety, insomnia, tinnitus, dizziness, headaches and injection-site reactions. Patients also reported hair loss, fatigue and mouth ulcers. Reported adverse reactions ceased once biosimilar was stopped and/or switching back to originator. All patients who reverted to originator due to reduced effectiveness reported a reduction in disease activity and improvement in symptoms. Conclusion: The vast majority of patients in our cohort on adalimumab were successfully switched from originator to ABP 501. The adalimumab biosimilar has been generally well-tolerated. 93% remained on biosimilar 24 weeks after switching, 4% have switched back to originator and 3% have either stopped or changed treatment. Reasons for switching back to originator from biosimilar included adverse reactions, most of which occurred within 24 hours, and also worsening of symptoms. The dynamics of the disease activity during treatment with TOFA Disclosure of Interests: None declared

13 October 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
Abdelrahman ElsayidAbdelrahman Elsayid
Abdelrahman Elsayid
VTVan Phu Tran
Van Phu Tran
RERanda Elsheikh
Randa Elsheikh
NHNguyen Thi Hien Hau
Nguyen Thi Hien Hau
SGSiti Mariam Abd Gani
Siti Mariam Abd Gani
Nguyen Tien HuyNguyen Tien Huy
Nguyen Tien Huy
The factors associated with hesitancy in receiving the COVID-19 vaccines have been widely examined by several studies worldwide. Although individual attitude plays a significant role in vaccine uptake, the WHO and public health experts believe that tackling the spread of COVID-19 is only achievable by guaranteeing vaccine equity across the globe, especially in low-and-middle-income countries, where the vaccination process is being hindered by other factors besides vaccine hesitancy. Among these factors is the refusal of the AstraZeneca vaccine because of its short shelf life. Therefore, we aimed in this letter to propose some solutions that may contribute to solving this specific problem.